sirpα antagonist (bi 765063): mechanism of action
Published 4 years ago • 2.8K plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
0:44
b7-h6/cd3 t-cell engager bi 765049 ± ezabenlimab in advanced solid tumors expressing b7-h6
-
4:46
secombit: sequencing of targeted agents/immunomodulatory abs in metastatic brafv600-mutated melanoma
-
1:12
rationale-306: exploring pd-l1 biomarker metrics in advanced escc
-
3:31
clinical trial: bi 765049 for cancer (nct04752215)
-
1:52
phase i trial of bi 764532, a t-cell engager for dll3-positive nec and sclc
-
1:24
kd033, a pdl1-1l15 bispecific molecule for the treatment of cancer
-
18:21
decisional tools to determine need for biopsy and re-biopsy in men with elevated psas
-
1:41
dr. harold j. burstein on cdk4/cdk6 inhibitor abemaciclib in breast cancer
-
17:57
sp1-77 antibody neutralizes all variants
-
2:12
cancer immunotherapy | the pd-l1 pathway
-
0:56
dr. bekaii-saab on tolerability of encorafenib, binimetinib, and cetuximab in braf crc
-
1:25
potential of ctcs for biomarker detection in prostate cancer
-
1:13
bi-specific antibodies in her2 gastric cancer
-
1:19
bio sb - 2021 new brg-1 / smarca4 antibody for ihc
-
2:48
clinical trial: bi 765179 for tumors (nct04958239)
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
2:19
bjc | tumour acidosis can predict metastatic potential in breast cancer
-
0:43
molecular testing for brca1 in ovarian cancer
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma